Background {#Sec1}
==========

Schizophrenia (SZ) is a common and complex multifactorial psychiatric disorder characterized by a variety of symptoms. These symptoms involve multiple psychological domains, including inferential thinking, attention, social interaction, expression of emotions, and volition. Typically, the onset of these symptoms starts manifesting in adolescence or early adulthood \[[@CR1], [@CR2]\]. Schizophrenia is a highly heritable and complex multifactorial illness; its heterogeneity is caused by both genetic and environmental factors and their interactions \[[@CR3], [@CR4]\]. High genetic risk for schizophrenia has led to considerable research efforts aimed at exploring its association with a number of candidate genes.

Although the biological etiology of schizophrenia is unknown, dopamine system dysfunction has been widely implicated in the pathogenesis of this disorder, and genes involved in dopaminergic pathways are being studied as candidate genes \[[@CR5], [@CR6]\]. Particular attention has been focused on the dopamine D2 receptor gene (*DRD2*). This is a transmembrane G protein-linked receptor which activates intracellular signaling by the inhibition of cAMP synthesis \[[@CR7]\]. In humans, the *DRD2* gene is localized on chromosome 11 at the q22--q23 locus. This gene presents multiple polymorphisms, about 514 (<http://snpper.chip.org/bio/snpper-enter/>). From these, we selected three functional variants \[[@CR8], [@CR9]\]. The C957T (rs6277) variant constitutes a polymorphism with a synonymous coding C\>T transition in exon 7. It has been proposed that this change influences the availability and affinity of the receptors \[[@CR10]--[@CR12]\]. Second, TaqI (rs1800497, C\>T) comprises a substitution of an acidic amino acid for a basic one (Glu713Lys), and the two alleles are referred as A2 (cytosine) and A1 (thymine), respectively. The A1 allele is considered the risk allele \[[@CR13], [@CR14]\]. Finally, the Ser311Cys (rs1801028, C\>G) polymorphism in exon 7 can present two variants, in which the C allele is the normal allele and encodes the amino acid serine (Ser) at codon 311, and the G allele is the risk allele and encodes a cysteine (Cys) \[[@CR15], [@CR16]\].

To date, a significant association between SZ and these functional *DRD2* gene polymorphisms (C957T, TaqI and Ser311Cys) has been reported by a number of authors \[[@CR17]--[@CR19]\]. However, several studies have failed to replicate this significant association \[[@CR14], [@CR20]\]. At least, two meta-analyses assessing the association between C957T, TaqI and Ser311Cys and schizophrenia have been performed. The first one was carried out by Yao et al. \[[@CR21]\] in 2014 and the second by Li et al. \[[@CR22]\] in 2015. Given that the dopamine system may contribute to the risk for schizophrenia, we conducted an update meta-analysis of all eligible published case--control studies to evaluate the effect of C957T, TaqI and Ser311Cys polymorphisms of the *DRD2* gene on the overall risk for SZ. The effects of ethnicity were also evaluated in this study.

Methods {#Sec2}
=======

The search association between SZ and *DRD2* gene variants was performed according to the following assessments: (1) a meta-analysis of the TaqI polymorphism in subjects with SZ compared to healthy controls, (2) meta-analysis of the C957T polymorphism in subjects with SZ compared to healthy controls, (3) meta-analysis of the Ser311Cys polymorphism in subjects with SZ compared to healthy controls, (4) meta-analysis of the TaqI polymorphism in schizophrenics versus healthy controls in the Caucasian population, (5) meta-analysis of the C957T polymorphism in schizophrenics versus healthy controls in Caucasian and Asian populations, and a further analysis in Chinese and Japanese subjects, (6) meta-analysis of the Ser311Cys polymorphism in schizophrenics versus healthy controls by population. (7) Finally, a meta-regression method based on age including TaqI, C957T, and Ser311Cys polymorphisms was performed.

The meta-analyses were reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement \[[@CR23], [@CR24]\]. The PRISMA checklist is included as Additional file [1](#MOESM1){ref-type="media"}.

Protocol registration {#Sec3}
---------------------

The protocol of this meta-analysis was registered in PROSPERO (<http://www.crd.york.ac.uk/prospero/>) with the registration number CRD42015029744.

Publication search {#Sec4}
------------------

To identify all potentially eligible studies on *DRD2* polymorphisms and schizophrenia risk, we performed a systematic search on PubMed and EBSCO databases that included all papers on the subject published up to February 2016. Relevant studies were identified using the terms: "*DRD2* AND C957T polymorphism AND schizophrenia", "*DRD2* AND rs6277 AND schizophrenia", "*DRD2* AND Ser311Cys polymorphism AND schizophrenia", "*DRD2* AND rs1801028 AND schizophrenia", "*DRD2* AND TaqI polymorphism AND schizophrenia", "*DRD2* AND rs1800497 AND schizophrenia" "DRD AND rs6277", "*DRD2* AND −141CInsDel". References within the retrieved articles and review articles were also screened. Citation lists of retrieved articles were manually examined to ensure search sensitivity.

Inclusion and exclusion criteria {#Sec5}
--------------------------------

Eligible studies had to meet the following criteria: (1) to be published in peer-reviewed journals, (2) to be designed as case--control studies, (3) to contain independent data, (4) to be association studies in which the frequencies of three genotypes were clearly stated or could be calculated, (5) inclusion of SZ diagnosis in the patient study group, and (6) the articles had to be written in English. Studies were excluded when: (1) they were not case--control studies, (2) they were reviews, comments or editorial articles, (3) they provided insufficient data, and (4) they were repeated studies.

Data extraction {#Sec6}
---------------

All the available data were extracted from each study by two researchers (Hernández-Díaz and González-Castro) working independently and in accordance with the inclusion criteria listed above. In case of disagreement in the inclusion, a third investigator was involved (Tovilla-Zárate) to resolve the discrepancy and a final decision was reached by the majority of votes. Data such as authors, year of publication, location, ethnic group, number of cases and controls, age, gender, SZ diagnosis of the participants and genotypes were collected.

Publication bias {#Sec7}
----------------

The possible presence of publication bias was evaluated graphically by drawing funnel plots and statistically by the Egger's standard regression test. In the Egger's test p \< 0.10 was considered a statistically significant publication bias. The shape of the funnel plots serve as an indication of any obvious asymmetry for the TaqI, C957T and Ser311Cys variants, which was additionally supported by the Egger's test. Moreover, to strengthen the analysis we evaluated publication bias by using the GRADE approach (Additional file [1](#MOESM1){ref-type="media"}). In addition, the 95% confidence interval (95% CI) of the effect size (ES) was also computed; effect size of 0.2 was regarded as small, effect size of 0.5 was considered moderate and ES greater than 0.8 was taken as large.

Quality score assessment {#Sec8}
------------------------

For inclusion in the systematic review, each study was independently assessed by two reviewers (YHD and TBGC) using the Newcastle--Ottawa Assessment Scale (NOS) to estimate the methodological quality \[[@CR25]\] (Table [1](#Tab1){ref-type="table"}). The quality score of a given study was based on a score of six as cut-off point to distinguish high from low quality studies.Table 1Characteristics of the studies included in this meta-analysisAuthorLocationNosNumberGenotypesp for HWECasesControlsCasesControlsCasesControlsA1/A1A1/A2A2/A2A1/A1A1/A2A2/A2Taq I Lafuente \[[@CR43]\]Spain880188227513681170.720.06 Monakhov \[[@CR44]\]Russia831136418910418238116100.510.48 Lafuente \[[@CR45]\]Spain828724358115713901840.200.58 Behravan \[[@CR17]\]Iran8386362111339210.01^a^0.52 Dubertret \[[@CR46]\]France810383712933040130.980.95 Aslan \[[@CR14]\]Turkey8991092970010630.00^a^0.00^a^ Comings \[[@CR63]\]USA4876958272591000.560.37 Sanders \[[@CR65]\]USA4555138161361230.620.20 Campion \[[@CR79]\]France5808060191582020.700.86 Nöthen \[[@CR56]\]Germany5606040182411810.980.51 Dollfus \[[@CR80]\]France6626141192114550.910.00^a^ Jonsson \[[@CR66]\]Sweden61046770304451840.740.24 Dubertret \[[@CR52]\]France7505036131262130.880.63 Parsons \[[@CR81]\]Spain811916592243936840.390.04^a^ Vijayan \[[@CR1]\]India821219410293178877290.620.08 Srivastava \[[@CR61]\]India82221381239362196210.02^a^0.00^a^AuthorLocationNosNumberGenotypesp for HWECasesControlsCasesControlsCasesControlsCCCT17TTCC107CTTTC957T Jonsson \[[@CR66]\]Sweden7173236160121232400.231.00 Lawford \[[@CR11]\]Australia61541484875312770510.870.73 Hanninen \[[@CR10]\]Finland71883845992371041761040.910.102 Kukreti \[[@CR47]\]India71011454138224864330.03^a^0.23 Hoenicka \[[@CR19]\]Spain7131364306140461741440.480.65 Mo \[[@CR48]\]China81741276196172969290.02^a^0.37 Luo \[[@CR49]\]China64663884095523513700.700.98 Monakhov \[[@CR44]\]Russia83113649915260781831030.900.91 Gupta \[[@CR41]\]India82542251041123876120290.410.09 Betcheva \[[@CR12]\]Bulgaria825555658128661922531110.890.09 Dubertret \[[@CR46]\]France71441421043731202110.920.94 Fan \[[@CR20]\]China84214033665233683410.430.55 Tsutsumi \[[@CR42]\]Japan94073843673813414320.980.64 Arinami \[[@CR27]\]Japan6260312190664193102170.790.50 Li \[[@CR82]\]England71511451123901182610.01^a^0.72 Ohara \[[@CR32]\]Japan7170121136340843610.370.30 Stöber \[[@CR64]\]Germany72602902075032365310.990.21 Breen (1) \[[@CR83]\]England73782922937872276140.470.96 Breen (2)Scotland71511451153331182610.710.72 Inada \[[@CR84]\]Japan723494156726514030.650.26 Tallerico \[[@CR85]\]Canada750514010043710.290.36 Hori \[[@CR39]\]Japan72412011627181425450.940.96 Himei \[[@CR40]\]Japan7190103118693712750.060.30 Dubertret \[[@CR52]\]France81038383191433370.930.79 Kapman \[[@CR86]\]Finland79394867088600.600.65 Parsons \[[@CR81]\]Spain8108153882001351800.590.28 Lafuente \[[@CR45]\]Spain82432912083322355420.630.75 Luu \[[@CR67]\]China82112011654421633440.600.24 Sanders \[[@CR57]\]Europe8187020021495354211643341180.990.94 Cordeiro \[[@CR68]\]Brazil8229733183388498206290.00^a^0.20 Srivastava \[[@CR61]\]India82332241616571724840.810.75 Kurt \[[@CR87]\]Turkey8736045262342510.710.26 Saiz \[[@CR88]\]Spain827240418176153019850.080.51 Xiao \[[@CR69]\]China812010096222682840.620.51^a^Significant p value

Statistical analysis {#Sec9}
--------------------

The comprehensive meta-analysis software (CMA, version 2) was used for the statistical analyses. The results are presented as odds ratios (ORs) and were used to assess the strength of the association between TaqI, C957T and Ser311Cys polymorphisms of the *DRD2* gene and SZ risk. Pooled ORs with their corresponding confidence intervals (95% CIs) were calculated for each of the models used: allelic (T vs C), additive (TT vs CC), dominant (TT + CT vs CC), and recessive (TT vs CT + TT). The estimated pooled ORs for each study were calculated using a random-effects model (Dersimonian and Laird method), though the fixed effects model was also considered (Mantel--Haenszel method). Heterogeneity of the studies was assessed with I^2^ and Q test statistics to identify significant outcomes. The sources of heterogeneity were also detected by sub-group analyses. Two sub-groups (Caucasian or Asian) according to different descents were analyzed for an ethnic-specific genetic comparison. Sample heterogeneity was analyzed with the Dersimonian and Laird's Q test. Q test results were complemented with graphs to help the visualization of those studies favoring heterogeneity. The reliability of the results was assessed by sensitivity analysis performed for all outcomes to determine whether the results were driven mainly by single studies. In addition, we performed a meta-regression method based on age, to reduce the small sample size problem. We also performed a cumulative meta-analysis to provide a framework for updating the genetic effect of all studies. For the cumulative meta-analysis, studies were sorted chronologically by year of publication. The Hardy--Weinberg equilibrium (HWE) was checked using a Chi square test in each case and control group of the included studies; values of p \< 0.05 were considered as showing a significant deviation from HWE. Finally, the strength of agreement between reviewers regarding study selection was evaluated by Kappa statistic.

Results {#Sec10}
=======

Characteristics of included studies {#Sec11}
-----------------------------------

On-line literature search supplemented with a manual search resulted in 285 reports comprising 86 case--control studies \[[@CR1], [@CR10]--[@CR12], [@CR14]--[@CR20], [@CR22], [@CR26]--[@CR69]\], which were included in this meta-analysis (Table [1](#Tab1){ref-type="table"}); this consisted of 18,692 SZ cases and 22,032 healthy controls. Of the 86 studies, 34 detailed the role of C957T in SZ, 36 examined the association of Ser311Cys with this disorder, and only 16 were available for the meta-analysis approach concerning the TaqI polymorphism and schizophrenia. In the case of TaqI, 12 studies were conducted in Caucasian populations, 2 in Indian, 1 in Iranian and 1 in Turkish populations, with a total of 1969 SZ cases and 1985 healthy controls. With regard to the C957T, 18 studies were conducted in Caucasians, 11 in Asians, 3 studies in Indians, 1 in Brazil and 1 in Turkish populations; in total 8819 SZ cases and 9965 healthy controls were included. Finally, for the Ser311Cys polymorphism, 18 studies were conducted in Asians, 15 in Caucasians and 3 in an Indian population with a total of 7827 SZ cases and 10,014 healthy controls. Characteristics of the 86 studies and the results of the HWE test are shown in Table [1](#Tab1){ref-type="table"}.

TaqI polymorphism and SZ {#Sec12}
------------------------

### All populations {#Sec13}

Seventeen studies were included to identify the association between TaqI and SZ risk. Following the same pattern of analysis previously established for *DRD2* gene variants, all the genetic models: *allelic* (OR 0.92, 95% CI 0.71--1.19), *additive* (OR 0.59, 95% CI 0.30--1.14), *recessive* (OR 1.34, 95% CI 0.88--2.05) and *dominant* (OR 0.72, 95% CI 0.49--1.06) showed heterogeneity with p \< 0.05. Subsequently, when we excluded the studies that favored the presence of the heterogeneity, we then observed the effect of the TaqI polymorphism in all populations using the *additive* genetic model (OR 0.57, 95% CI 0.38--0.86; p value of Q test: 0.32) and found a protective effect in the population as a whole. However, when we analyzed the *recessive model,* a risk effect was encountered (OR 1.50, 95% CI 1.10--2.03; p value of Q test: 0.66); see Table [2](#Tab2){ref-type="table"}). The Egger's test did not yield evidence of publication bias (Fig. [1](#Fig1){ref-type="fig"}). To reduce the effect of the small size of the sample in the analyses, we performed a meta-regression method based on age for the whole population. This analysis revealed a point estimate slope of −0.05365 and p value of 0.01686 (Fig. [2](#Fig2){ref-type="fig"}).Table 2Analysis of the association studies between the *DRD2* gene TaqI polymorphism and SZ in all populations and in a Caucasian sub-groupModel analysisModel effectsp value of Q testRandom\
OR (95% CI)Fixed\
OR (95% CI)All populations AllelicWith heterogeneity0.92 (0.71--1.19)*0.89 (0.80--0.99)*\<0.00Without heterogeneity0.92 (0.79--1.07)0.92 (0.81--1.05)0.256 AdditiveWith heterogeneity0.59 (0.30--1.14)*0.51 (0.37--0.71)*\<0.00Without heterogeneity*0.57 (0.38--0.86)0.57 (0.39--0.81)*0.326 RecessiveWith heterogeneity1.34 (0.88--2.05)1.17 (0.95--1.44)\<0.00Without heterogeneity*1.50 (1.10--2.03)1.50 (1.10--2.03)*0.664 DominantWith heterogeneity0.72 (0.49--1.06)*0.72 (0.62--0.84)*\<0.00Without heterogeneity0.85 (0.72--1.01)0.85 (0.72--1.01)0.586Caucasian population AllelicWith heterogeneity0.88 (0.66--1.18)*0.86 (0.77--0.96)*\<0.00Without heterogeneity0.86 (0.71--1.05)0.86 (0.71--1.05)0.551 AdditiveWith heterogeneityWithout heterogeneity*0.60 (0.36--0.99)0.59 (0.39--0.91)*0.263 RecessiveWith heterogeneityWithout heterogeneity0.90 (0.69--1.18)0.90 (0.71--1.15)0.403 DominantWith heterogeneity0.76 (0.50--1.14)*0.77 (0.64--0.93)*\<0.00Without heterogeneity0.89 (0.71--1.11)0.89 (0.72--1.10)0.397Italic values denote significant value, p \< 0.05 Fig. 1**a** Flow-chart design to show the inclusion of studies in this meta-analysis. **b** Forest plots of the allelic model for TaqI. **c** Forest plots of the dominant model for TaqI. **d** Begg's funnel plot analysis of publication bias in the allelic model for TaqI Fig. 2Meta-regression method based on age in the population as a whole. **a** TaqI polymorphism and **b** C957T polymorphism

### Caucasian population {#Sec14}

Given that previous studies have reported a positive association between TaqI and SZ risk in Caucasians \[[@CR46]\], we decided to conduct a meta-analysis on the Caucasian population. This sub-group analysis by ethnicity included seven studies which showed no evidence of any association between TaqI and SZ in Caucasian populations. The results for the different genetic models were: *allelic* (OR 0.86, 95% CI 0.71--1.05; p value of Q test: 0.55), *recessive* (OR 0.90, 95% CI 0.69--1.18; p value of Q test: 0.40) and *dominant* (OR 0.89, 95% CI 0.71--1.11; p value of Q test: 0.39). However, in the *additive* model we observed a protective effect of TaqI on schizophrenia (OR 0.60, 95% CI 0.36--0.99; p value of Q test: 0.26) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3**a** Forest plots of the allelic model for TaqI in Caucasians. **b** Begg's funnel plot analysis of publication bias of the allelic model for TaqI in Caucasians. **c** Forest plots of the dominant model for TaqI in Caucasians. **d** Begg's funnel plot analysis of publication bias in the dominant model for TaqI in Caucasians

C957T polymorphism and schizophrenia {#Sec15}
------------------------------------

### All populations {#Sec16}

We performed an analysis in the population as a whole to explore the probable risk role of the C957T polymorphism in schizophrenia. Initially, we conducted a meta-analysis with the four genetic models proposed: *allelic* (OR 0.92, 95% CI 0.81--1.05), *additive* (OR 0.77, 95% CI 0.57--1.05), *recessive* (OR 0.84, 95% CI 0.66--1.06) and *dominant* (OR 0.91, 95% CI 0.78--1.05), in which p of Q test \<0.05 indicated heterogeneity. No statistical association was found between the C957T polymorphism and schizophrenia. However, when we discarded the studies favoring heterogeneity, we obtained the following outcomes of statistical association for the models: *additive* (OR 0.75, 95% CI 0.58--0.97; p value of Q test: 0.15) and *recessive* (OR 0.79; 95% CI 0.64--0.98; p value of Q test: 0.21) (Table [3](#Tab3){ref-type="table"}). In addition, the Egger's test revealed no evidence of publication bias (Fig. [4](#Fig4){ref-type="fig"}). With regard to the meta-regression based on age, the slope was 0.00849 and the p value 0.38756 (Fig. [2](#Fig2){ref-type="fig"}).Table 3Analysis of association studies between the *DRD2* gene C957T polymorphism and schizophrenia by populationsModel analysisModel effectsp value of Q testRandom\
OR (95% CI)Fixed\
OR (95% CI)All populations AllelicWith heterogeneity0.92 (0.81--1.05)*0.93 (0.87--0.98)*\<0.00Without heterogeneity1.03 (0.93--1.15)1.03 (0.93--1.15)0.595 AdditiveWith heterogeneity0.77 (0.57--1.05)*0.76 (0.65--0.89)*\<0.00Without heterogeneity*0.75 (0.58--0.97)0.74 (0.61--0.91)*0.151 RecessiveWith heterogeneity0.84 (0.66--1.06)0.82 (0.72--0.94)\<0.00Without heterogeneity*0.79 (0.64--0.98)0.78 (0.66--0.92)*0.211 DominantWith heterogeneity0.91 (0.78--1.05)0.94 (0.88--1.01)\<0.00Without heterogeneity0.89 (0.77--1.03)0.89 (0.78--1.02)0.308Caucasian population AllelicWith heterogeneity0.98 (0.81--1.18)0.98 (0.91--1.05)\<0.00Without heterogeneity1.03 (0.88--1.21)1.00 (0.87--1.14)0.252 AdditiveWith heterogeneity0.85 (0.54--1.34)*0.80 (0.66--0.97)*\<0.00Without heterogeneity0.94 (0.63--1.40)0.90 (0.63--1.27)0.354 RecessiveWith heterogeneity0.89 (0.65--1.23)*0.83 (0.71--0.98)*\<0.00Without heterogeneity*0.73 (0.60--0.89)0.73 (0.60--0.89)*0.440 DominantWith heterogeneity0.98 (0.79--1.21)1.03 (0.93--1.13)\<0.00Without heterogeneity1.04 (0.89--1.21)1.03 (0.89--1.20)0.400Asian population AllelicWith heterogeneity0.84 (0.66--1.07)*0.82 (0.73--0.93)*\<0.00Without heterogeneity*0.66 (0.52--0.83)0.66 (0.52--0.83)*0.725 AdditiveWith heterogeneityWithout heterogeneity*0.49 (0.28--0.86)0.45 (0.29--0.70)*0.206 RecessiveWith heterogeneityWithout heterogeneity*0.52 (0.32--0.83)0.49 (0.32--0.75)*0.330 DominantWith heterogeneity0.84 (0.64--1.10)*0.85 (0.73--0.99)*\<0.00Without heterogeneity*0.61 (0.50--0.74)0.61 (0.50--0.74)*0.864Italic values denote significant value, p \< 0.05 Fig. 4**a** Forest plots of the allelic model for C957T. **b** Begg's funnel plot analysis of publication bias in the allelic model for C957T. **c** Forest plots of the dominant model for C957T. **d** Begg's funnel plot analysis of publication bias in the dominant model for C957T

### Caucasian population {#Sec17}

We performed a stratified analysis by ethnicity to measure SZ risk by populations. With regard to Caucasians, the first outcomes with a p of Q test \<0.05 showed evidence of heterogeneity in the *allelic* (OR 0.98, 95% CI 0.81--1.18), *additive* (OR 0.85, 95% CI 0.54--1.34), *recessive* (OR 0.89, 95% CI 0.65--1.23) and *dominant* (OR 0.98, 95% CI 0.79--1.21) models. Subsequently, when heterogeneity was discarded, the outcome presented a positive association with schizophrenia in the *allelic* model (OR 0.73, 95% CI 0.60--0.89; p value of Q test: 0.44). However, a slight possibility of an association in the *additive* (OR 0.80, 95% CI 0.66--0.97; p value of Q test \<0.00) and *recessive* (OR 0.83, 95% CI 0.71--0.98; p value of Q test \<0.00) models could be suggested. But since these findings were in the presence of heterogeneity and using the fixed effects model, we did not consider them for the analysis. For all the analyses in Caucasians, the p value of the Egger's test suggested the non-existence of publication bias (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5**a** Forest plots of the allelic model for C957T in Caucasians. **b** Begg's funnel plot analysis of publication bias in the allelic model for C957T in Caucasians. **c** Forest plots of the dominant model for C957T in Caucasians. **d** Begg's funnel plot analysis of publication bias in the dominant model for C957T in Caucasians

### Asian population {#Sec18}

Finally, for the C957T polymorphism in the Asian population we followed the same pattern of analysis as in the previous sub-section. In the initial analysis the outcomes exhibited the presence of heterogeneity (p \< 0.05) in the *allelic* (OR 0.84, 95% CI 0.66--1.07) and *dominant* models (OR 0.84, 95% CI 0.64--1.10). After we excluded the studies that favored heterogeneity, the results evidenced an association between the C957T polymorphism and SZ in the four models: *allelic* (OR 0.66, 95% CI 0.52--0.83; p value of Q test: 0.72), *additive* (OR 0.49, 95% CI 0.28--0.86; p value of Q test: 0.20), *recessive* (OR 0.52, 95% CI 0.32--0.83; p value of Q test: 0.33) and *dominant* (OR 0.61, 95% CI 0.50--0.74; p value of Q test: 0.061), using the random effects method. However, we want to emphasize that the outcomes showed the same protective association between C957T and SZ in the all models when we used the fixed effects model.

C957T polymorphism in Chinese and Japanese populations {#Sec19}
------------------------------------------------------

In order to perform a more comprehensive and comparative meta-analysis we conducted two more sub-analyses, but only for the subjects born in Japan and in China. These sub-analyses helped to compare our findings with previous published met-analyses. Initially, we selected the studies that explored the role of C957T in Japanese schizophrenics and found a relation to SZ in the four models without heterogeneity, viz.: *allelic* (OR 0.69, 95% CI 0.57--0.85; p value of Q test: 0.11), *additive* (OR 0.51, 95% CI 0.27--0.95; p value of Q test: 0.24), *recessive* (OR 0.54, 95% CI 0.29--0.99; p value of Q test: 0.27) and *dominant* (OR 0.58, 95% CI 0.45--0.76; p value of Q test: 0.98), but all the results were for the fixed effects model. Nevertheless, when we used the random effects method we encountered the same pattern only in the *allelic* (OR 0.71, 95% CI 0.53--0.94) and *dominant* (OR 0.58, 95% CI 0.45--0.76) models. With regard to the Chinese population, we found a similar association to that of the previous sub-analysis. Interestingly, we found a risk effect in the *allelic* (OR 1.33, 95% CI 1.04--1.70; p value of Q test: 0.50) and *dominant* (OR 1.36, 95% CI 1.04--1.77; p value of Q test: 0.69) models, without heterogeneity using the random effects method (Table [4](#Tab4){ref-type="table"}).Table 4Analysis of association studies between the *DRD2* C957T polymorphism and schizophrenia in China and JapanModel analysisModel effectsp value of Q testRandom\
OR (95% CI)Fixed\
OR (95% CI)Japan AllelicWith heterogeneity0.79 (0.58--1.07)*0.78 (0.66--0.93)*0.017Without heterogeneity*0.71 (0.53--0.94)0.69 (0.57--0.85)*0.112 AdditiveWith heterogeneityWithout heterogeneity0.50 (0.24--1.07)*0.51 (0.27--0.95)*0.243 RecessiveWith heterogeneityWithout heterogeneity0.53 (0.26--1.08)*0.54 (0.29--0.99)*0.279 DominantWith heterogeneity0.79 (0.55--1.14)*0.78 (0.64--0.96)*0.011Without heterogeneity*0.58 (0.45--0.76)0.58 (0.45--0.76)*0.988China AllelicWith heterogeneity0.95 (0.62--1.45)0.92 (0.77--1.11)\<0.00Without heterogeneity*1.33 (1.04--1.70)1.33 (1.04--1.70)*0.507 AdditiveWith heterogeneityWithout heterogeneity0.55 (0.21--1.39)*0.40 (0.22--0.73)*0.173 RecessiveWith heterogeneityWithout heterogeneity0.54 (0.25--1.15)*0.46 (0.26--0.79)*0.283 DominantWith heterogeneity0.96 (0.62--1.48)1.02 (0.82--1.28)\<0.00Without heterogeneity*1.36 (1.04--1.77)1.36 (1.04--1.77)*0.697Italic values denote significant value, p \< 0.05

Ser311Cys polymorphism and SZ {#Sec20}
-----------------------------

For this polymorphism the meta-analysis was performed for the overall population. The outcomes in Caucasian and Asian populations were similar to those found for the previous variants. Since the present work showed the same results as in previous studies \[[@CR21]\], we will not discuss this polymorphism in the present work. However, we present the details in Additional file [2](#MOESM2){ref-type="media"}.

Sensitivity analysis {#Sec21}
--------------------

In addition, a sensitivity analysis was carried out in which one study at a time was excluded to determine whether a specific study was favoring a marked heterogeneity. Nevertheless, the presence of heterogeneity was not explained by just one study. Furthermore, to measure the effects over time on the studies, we performed a cumulative meta-analysis, in which individual data sets were ordered chronologically (Additional file [3](#MOESM3){ref-type="media"}).

Discussion {#Sec22}
==========

Schizophrenia is a complex genetic disorder manifesting combined environmental and genetic factors. Several studies have suggested that genetic variants of the *DRD2* gene play a role in SZ etiology \[[@CR70], [@CR71]\]. To assess the relationship between the *DRD2* genetic variants and the risk to develop schizophrenia, we conducted a meta-analysis of three *DRD2* polymorphisms: TaqI, C957T and Ser311Cys. The meta-analysis approach is a powerful tool to summarize contradicting results from different studies and has been used to analyze the role of various genes in schizophrenia \[[@CR54], [@CR72], [@CR73]\].

First, we performed the analysis of the TaqI polymorphism to assess the role of this genetic variant in schizophrenia. There was a protective effect in the additive model in the population as a whole and in Caucasians. Also, we found a risk effect when using the recessive model in the combined results of the analysis for all populations. However, various studies have reported that TaqI polymorphism does not play an important role in the psychopathological symptoms of schizophrenia, whereas other researches agree with our results \[[@CR21], [@CR22], [@CR63], [@CR66]\]. One of the reasons for this discrepancy could be the relative small size of the sample, which limits the statistical power for the detection of a relationship between the TaqI polymorphism and schizophrenia \[[@CR72]\]; more studies are needed to further validate these results. Another explanation is the environmental exposure that could trigger the expression of a gene, and this in turn could modify other genes which may then interact with *DRD2* and increase the risk to present the disease. In spite of the contrasting outcomes published, the role of TaqI has been more related to substance abuse, since the less frequent allele (A1 allele) has been associated with some psychiatric disorders such as alcoholism and substance abuse \[[@CR74], [@CR75]\]. On the other hand, previous studies have demonstrated that subjects with one or two A1 alleles of the *DRD2* polymorphism at the Taq1 A locus present lower *DRD2* density than those with no A1 allele \[[@CR76]\]. Also, other studies have shown that female patients with the A1 allele exhibit greater prolactin response to nemonapride, a selective antagonist for D2-like dopamine receptors in schizophrenic patients \[[@CR77]\]. Due to this association between TaqI and schizophrenia, the A1 allele has been suggested to diminish dopaminergic activity in the central nervous system \[[@CR78]\].

For the C957T polymorphism, the comparisons performed in our study showed a significant positive association between this polymorphism and SZ in the overall population and in Caucasian and Asian sub-groups. In this sense, we recognize the existence of two previous meta-analyses \[[@CR21], [@CR22]\], in which many differences are observed: first, we identified a protective effect of the T allele of C957T using the additive and recessive models when analyzing the population as a whole, as well as when using the recessive model in Caucasians and the four genetic models in Asians. In contrast, Yao et al. did not observe any association. The differences could be due to the size of the samples. Our present study used 8819 SZ patients and 9965 healthy controls compared with 6075 SZ and 6643 controls of the previous meta-analysis by Yao et al. \[[@CR21]\]. We included 2792 cases and 3322 controls more. In the Asian population a protective effect was found in all the models we used. As a consequence, we decided to perform an analysis by Asiatic subpopulations. Therefore, we divided the Asian population into Chinese and Japanese samples. In these sub-analyses we encountered unexpected results: the Chinese population showed an increased risk, whereas the Japanese population showed a protective association. This is clear an "allele paradox" between populations that may reflect the difference in the distribution of allele frequencies across the geographical localization. Our results draw attention to the influence of other factors such as the environment, which could be acting with ethnicity in this genetic association.

There are several limitations in this study. First, the sample size for some sub-group analyses was limited; therefore, more studies with larger samples should be included to enhance the reliability and stability of the meta-analysis. Second, a language bias may be present given that only studies published in English were included. Third, due to the limitation of the data, we did not stratify according to other potential factors which may enhance the risk for the development of SZ, such as gender, age of onset and clinical manifestations.

Conclusions {#Sec23}
===========

The meta-analysis indicated that TaqI and C957T polymorphisms show a protective effect against SZ. In the sub-analysis of the C957T polymorphism we observed that this variant may contribute to the occurrence of schizophrenia in Chinese subjects, so the influence of ethnicity could be important in modifying the role of this polymorphism in SZ. Given the limitations of the studies included in the meta-analysis, future studies with larger samples and prospective designs are needed to fully understand the relationship between these polymorphisms and SZ. However, this meta-analysis still provides new insights into the role of the *DRD2* gene in SZ risk.

Additional files {#Sec24}
================

**Additional file 1.** Grades quality assessment and PRISMA check list. **Additional file 2.** Association of the C957T polymorphism and schizophrenia. **Additional file 3.** Sensitivity analysis and cumulative meta-analysis.

DRD2

:   dopamine D2 receptor
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:   schizophrenia
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:   Newcastle--Ottawa Assessment Scale
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:   preferred reporting items for systematic reviews and meta-analyses

HWE

:   Hardy--Weinberg equilibrium
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